{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T14:21:09Z","timestamp":1780496469131,"version":"3.54.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2008,8,28]],"date-time":"2008-08-28T00:00:00Z","timestamp":1219881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2008,8,28]],"date-time":"2008-08-28T00:00:00Z","timestamp":1219881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1038\/leu.2008.214","type":"journal-article","created":{"date-parts":[[2008,8,28]],"date-time":"2008-08-28T09:48:50Z","timestamp":1219916930000},"page":"2048-2053","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":85,"title":["Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia"],"prefix":"10.1038","volume":"22","author":[{"given":"J E","family":"Castro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J D","family":"Sandoval-Sus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Bole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Rassenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T J","family":"Kipps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,8,28]]},"reference":[{"key":"BFleu2008214_CR1","doi-asserted-by":"publisher","first-page":"4070","DOI":"10.1200\/JCO.2005.12.516","volume":"23","author":"W Wierda","year":"2005","unstructured":"Wierda W, O'Brien S, Wen S, Faderl S, Garcia-Manero G, Thomas D et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 4070\u20134078.","journal-title":"J Clin Oncol"},{"key":"BFleu2008214_CR2","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1046\/j.1365-2141.2002.03959.x","volume":"119","author":"F Bosch","year":"2002","unstructured":"Bosch F, Ferrer A, Lopez-Guillermo A, Gine E, Bellosillo B, Villamor N et al. Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. Br J Haematol 2002; 119: 976\u2013984.","journal-title":"Br J Haematol"},{"key":"BFleu2008214_CR3","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1007\/s00262-005-0010-0","volume":"55","author":"BD Cheson","year":"2006","unstructured":"Cheson BD . Monoclonal antibody therapy of chronic lymphocytic leukemia. Cancer Immunol Immunother 2006; 55: 188\u2013196.","journal-title":"Cancer Immunol Immunother"},{"key":"BFleu2008214_CR4","doi-asserted-by":"publisher","first-page":"3554","DOI":"10.1182\/blood.V99.10.3554","volume":"99","author":"MJ Keating","year":"2002","unstructured":"Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large International Study. Blood 2002; 99: 3554\u20133561.","journal-title":"Blood"},{"key":"BFleu2008214_CR5","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.1200\/JCO.2002.06.119","volume":"20","author":"KR Rai","year":"2002","unstructured":"Rai KR, Freter CE, Mercier RJ, Cooper MR, Mitchell BS, Stadtmauer EA et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 2002; 20: 3891\u20133897.","journal-title":"J Clin Oncol"},{"issue":"2 Suppl 5","key":"BFleu2008214_CR6","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1053\/j.seminoncol.2006.01.025","volume":"33","author":"KR Rai","year":"2006","unstructured":"Rai KR . Novel therapeutic strategies with alemtuzumab for chronic lymphocytic leukemia. Semin Oncol 2006; 33 (2 Suppl 5): S15\u2013S22.","journal-title":"Semin Oncol"},{"key":"BFleu2008214_CR7","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1200\/JCO.2001.19.8.2153","volume":"19","author":"JC Byrd","year":"2001","unstructured":"Byrd JC, Murphy T, Howard RS, Lucas MS, Goodrich A, Park K et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001; 19: 2153\u20132164.","journal-title":"J Clin Oncol"},{"key":"BFleu2008214_CR8","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1200\/JCO.2001.19.8.2165","volume":"19","author":"SM O'Brien","year":"2001","unstructured":"O'Brien SM, Kantarjian H, Thomas DA, Giles FJ, Freireich EJ, Cortes J et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001; 19: 2165\u20132170.","journal-title":"J Clin Oncol"},{"key":"BFleu2008214_CR9","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3109\/10428199909083393","volume":"34","author":"PD Thornton","year":"1999","unstructured":"Thornton PD, Hamblin M, Treleaven JG, Matutes E, Lakhani AK, Catovsky D . High dose methyl prednisolone in refractory chronic lymphocytic leukaemia. Leuk Lymphoma 1999; 34: 167\u2013170.","journal-title":"Leuk Lymphoma"},{"key":"BFleu2008214_CR10","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1182\/blood.V99.3.1030","volume":"99","author":"N Tsukada","year":"2002","unstructured":"Tsukada N, Burger JA, Zvaifler NJ, Kipps TJ . Distinctive features of \u2018nurselike\u2019 cells that differentiate in the context of chronic lymphocytic leukemia. Blood 2002; 99: 1030\u20131037.","journal-title":"Blood"},{"key":"BFleu2008214_CR11","first-page":"3767a","volume":"98","author":"N Tsukada","year":"2001","unstructured":"Tsukada N, Kitada S, Reed JC, Kipps TJ . Combination rituximab and methylprednosolone mitigate the protective activity of nurse-like cells on leukemia cell viability in vitro. Blood 2001; 98: 3767a.","journal-title":"Blood"},{"key":"BFleu2008214_CR12","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990","volume":"87","author":"BD Cheson","year":"1996","unstructured":"Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990\u20134997.","journal-title":"Blood"},{"key":"BFleu2008214_CR13","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1056\/NEJMoa040857","volume":"351","author":"LZ Rassenti","year":"2004","unstructured":"Rassenti LZ, Huynh L, Toy TL, Chen L, Keating MJ, Gribben JG et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004; 351: 893\u2013901.","journal-title":"N Engl J Med"},{"key":"BFleu2008214_CR14","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1182\/blood.V98.9.2633","volume":"98","author":"G Del Poeta","year":"2001","unstructured":"Del Poeta G, Maurillo L, Venditti A, Buccisano F, Epiceno AM, Capelli G et al. Clinical significance of CD38 expression in chronic lymphocytic leukemia. Blood 2001; 98: 2633\u20132639.","journal-title":"Blood"},{"key":"BFleu2008214_CR15","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","volume":"343","author":"H Dohner","year":"2000","unstructured":"Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910\u20131916.","journal-title":"N Engl J Med"},{"key":"BFleu2008214_CR16","first-page":"22","volume-title":"American College of Medical Genetics, Standards and Guidelines for Clinical Genetics Laboratories","author":"MS Watson","year":"1999","unstructured":"Watson MS (ed). American College of Medical Genetics, Standards and Guidelines for Clinical Genetics Laboratories, edn. American College of Medical Genetics: Bethesda, MD 1999, pp 22\u201336."},{"key":"BFleu2008214_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon R . Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1\u201310.","journal-title":"Control Clin Trials"},{"key":"BFleu2008214_CR18","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457\u2013481.","journal-title":"J Am Stat Assoc"},{"key":"BFleu2008214_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/bjc.1977.1","volume":"35","author":"R Peto","year":"1977","unstructured":"Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer 1977; 35: 1\u201339.","journal-title":"Br J Cancer"},{"key":"BFleu2008214_CR20","first-page":"1163","volume-title":"Williams Hematology","author":"TJ Kipps","year":"2001","unstructured":"Kipps TJ . Chronic lymphocytic leukemia and related diseases. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, Seligsohn U (eds). Williams Hematology, 6th edn. McGraw-Hill, Inc.: New York, 2001, pp 1163\u20131194."},{"key":"BFleu2008214_CR21","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3109\/10428199509059650","volume":"18","author":"JF Seymour","year":"1995","unstructured":"Seymour JF, Robertson LE, O'Brien S, Lerner S, Keating MJ . Survival of young patients with chronic lymphocytic leukemia failing fludarabine therapy: a basis for the use of myeloablative therapies. Leuk Lymphoma 1995; 18: 493\u2013496.","journal-title":"Leuk Lymphoma"},{"key":"BFleu2008214_CR22","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1200\/JCO.2001.19.5.1414","volume":"19","author":"SM O'Brien","year":"2001","unstructured":"O'Brien SM, Kantarjian HM, Cortes J, Beran M, Koller CA, Giles FJ et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol 2001; 19: 1414\u20131420.","journal-title":"J Clin Oncol"},{"key":"BFleu2008214_CR23","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1182\/blood.V82.6.1695.1695","volume":"82","author":"S O'Brien","year":"1993","unstructured":"O'Brien S, Kantarjian H, Beran M, Smith T, Koller C, Estey E et al. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood 1993; 82: 1695\u20131700.","journal-title":"Blood"},{"key":"BFleu2008214_CR24","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1182\/blood.V74.1.19.19","volume":"74","author":"MJ Keating","year":"1989","unstructured":"Keating MJ, Kantarjian H, Talpaz M, Redman J, Koller C, Barlogie B et al. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood 1989; 74: 19\u201325.","journal-title":"Blood"},{"key":"BFleu2008214_CR25","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1046\/j.1365-2141.2001.02959.x","volume":"114","author":"M Hallek","year":"2001","unstructured":"Hallek M, Schmitt B, Wilhelm M, Busch R, Krober A, Fostitsch HP et al. Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group. Br J Haematol 2001; 114: 342\u2013348.","journal-title":"Br J Haematol"},{"key":"BFleu2008214_CR26","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1182\/blood-2002-04-1258","volume":"101","author":"JC Byrd","year":"2003","unstructured":"Byrd JC, Peterson BL, Morrison VA, Park K, Jacobson R, Hoke E et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003; 101: 6\u201314.","journal-title":"Blood"},{"key":"BFleu2008214_CR27","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s00277-003-0710-5","volume":"82","author":"PD Thornton","year":"2003","unstructured":"Thornton PD, Matutes E, Bosanquet AG, Lakhani AK, Grech H, Ropner JE et al. High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities. Ann Hematol 2003; 82: 759\u2013765.","journal-title":"Ann Hematol"},{"key":"BFleu2008214_CR28","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00262-005-0015-8","volume":"55","author":"F Ravandi","year":"2006","unstructured":"Ravandi F, O'Brien S . Immune defects in patients with chronic lymphocytic leukemia. Cancer Immunol Immunother 2006; 55: 197\u2013209.","journal-title":"Cancer Immunol Immunother"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2008214.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2008214","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2008214.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T11:10:34Z","timestamp":1648725034000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2008214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8,28]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["BFleu2008214"],"URL":"https:\/\/doi.org\/10.1038\/leu.2008.214","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8,28]]},"assertion":[{"value":"21 February 2008","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2008","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2008","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2008","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}